Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Miguel Brito-Sanfiel"'
Autor:
Jean-François Yale, Jeremy Hodson Pettus, Miguel Brito-Sanfiel, Fernando Lavalle-Gonzalez, Ana Merino-Trigo, Peter Stella, Soazig Chevalier, Raffaella Buzzetti
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190579 (2018)
To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs.A po
Externí odkaz:
https://doaj.org/article/8a5e9a7e1ac64e8eb639da9f0c475957
Autor:
Almodóvar-Ruiz, Juan J. Gorgojo-Martinez, Pablo José Ferreira-Ocampo, Alba Galdón Sanz-Pastor, Jersy Cárdenas-Salas, Teresa Antón-Bravo, Miguel Brito-Sanfiel, Francisca
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 13; Pages: 4248
Aim: This study aimed to evaluate the effectiveness and tolerability of intensifying the dose of canagliflozin from 100 mg/day (CANA100) to 300 mg/day (CANA300) in patients with type 2 diabetes (T2DM) and suboptimal metabolic control in a real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::69e99736702979c28e46348fbd35100e
Autor:
Jaime E.M. Wong-Cruz, Miguel Brito-Sanfiel, Manuel Gargallo-Fernández, Teresa Antón-Bravo, Alba Galdón Sanz-Pastor, Juan J. Gorgojo-Martinez
Publikováno v:
Diabetology
Volume 2
Issue 3
Pages 15-175
Volume 2
Issue 3
Pages 15-175
The observational Real-Wecan study showed that canagliflozin 100 mg (CANA100) as an add-on therapy, and canagliflozin 300 (CANA300), switching from prior SGLT-2i therapy, significantly improved several cardiometabolic parameters in patients with T2DM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d35eaecd07a5ee24d1cb70947623cf8
https://doi.org/10.3390/diabetology2030015
https://doi.org/10.3390/diabetology2030015
Autor:
Tejera-Pérez, Cristina, Chico, Ana, Azriel-Mira, Sharona, Lardiés-Sánchez, Beatriz, Gomez-Peralta, Fernando, Jesús, Amor Fernández Antonio, Amparo, Bartual Rodrigo, Virginia, Bellido, Diego, Bellido Guerrero, Antonio, Botana López Manuel, Miguel, Brito Sanfiel, Gloria, Canovas Molina, Daniel, Cepero Garcia, Ana, Chico Ballesteros, Ignacio, Conget Donlo, Antonio, de Luis Román Daniel, María, Durán Martínez, Alejandra, Duran Rodriguez-Hervada, Javier, Escalada San Martin Francisco, Carlos, Fernández García José
Publikováno v:
Diabetes Therapy; Jul2023, Vol. 14 Issue 7, p1077-1091, 15p
Autor:
Juan J. Gorgojo-Martinez, Miguel Brito-Sanfiel, Teresa Antón-Bravo, Alba Galdón Sanz-Pastor, Jaime Wong-Cruz, Manuel A. Gargallo Fernández
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 19; Pages: 5622
The Real-WECAN study evaluated the real-life effectiveness and safety of canagliflozin 100 mg daily (initiated in SGLT-2 inhibitors naïve patients) and canagliflozin 300 mg daily (switching from canagliflozin 100 mg or other SGLT-2 inhibitors) in in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f6e5db55329d7078ae7b2aacee00720
https://doi.org/10.3390/jcm11195622
https://doi.org/10.3390/jcm11195622
Autor:
Jaime E.M. Wong-Cruz, Miguel Brito-Sanfiel, Manuel Gargallo-Fernández, Alba Galdón Sanz-Pastor, Teresa Antón-Bravo, Juan J. Gorgojo-Martinez
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 7
Journal of Clinical Medicine, Vol 9, Iss 2275, p 2275 (2020)
Volume 9
Issue 7
Journal of Clinical Medicine, Vol 9, Iss 2275, p 2275 (2020)
The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d33705a2fe17cf8fa45f984b16ced3c4
Autor:
Teresa Antón-Bravo, Juan J. Gorgojo-Martinez, Miguel Brito-Sanfiel, Jaime E.M. Wong-Cruz, Manuel Gargallo-Fernández, Alba Galdon
Publikováno v:
Diabetes. 69
The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as add-on to the background antihyperglycemic therapy, and to evaluate the intensification of SG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84645583b35bf0ec3626c1501b01c2a5
https://doi.org/10.2337/db20-1127-p
https://doi.org/10.2337/db20-1127-p
Autor:
Teresa Antón-Bravo, Miguel Brito-Sanfiel, Manuel Gargallo-Fernández, Juan J. Gorgojo-Martinez, Jaime E.M. Wong-Cruz, Alba Galdon
Publikováno v:
Diabetes. 69
The aim of this multicentric retrospective study was to assess in a real-world setting kidney outcomes associated with canagliflozin 100 mg/d (CANA100), as add-on to the background antihyperglycemic therapy, and with the intensification of SGLT2 inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e249d9d836926411bb07e10fa818d63a
https://doi.org/10.2337/db20-2220-pub
https://doi.org/10.2337/db20-2220-pub
Autor:
Peter Stella, Jeremy Pettus, Ana Merino-Trigo, Miguel Brito-Sanfiel, Jean-François Yale, Raffaella Buzzetti, Soazig Chevalier, Fernando J. Lavalle-González
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190579 (2018)
PLoS ONE
PloS one, vol 13, iss 1
PLoS ONE
PloS one, vol 13, iss 1
Author(s): Yale, Jean-Francois; Pettus, Jeremy Hodson; Brito-Sanfiel, Miguel; Lavalle-Gonzalez, Fernando; Merino-Trigo, Ana; Stella, Peter; Chevalier, Soazig; Buzzetti, Raffaella | Abstract: AimsTo evaluate the effect of concomitant dipeptidyl peptid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01555dbdf8bc6f5002586118a8041e3a
http://europepmc.org/articles/PMC5784896?pdf=render
http://europepmc.org/articles/PMC5784896?pdf=render
Autor:
Arturo Lisbona-Catalán, Miguel Brito-Sanfiel, Manuel Gargallo-Fernández, Juan J. Gorgojo-Martinez
Publikováno v:
International journal of clinical practice. 72(3)
Aims To evaluate in a real-world setting the effectiveness of exenatide once-weekly (ExQW) in patients with T2D and to determine predictors of glycaemic and weight response to this drug at 6 months. Methods Observational, retrospective, multicenter s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4e773e3e26bc7656a105d63f8faa4d3
https://pubmed.ncbi.nlm.nih.gov/29341370
https://pubmed.ncbi.nlm.nih.gov/29341370